Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
72.73 USD | +1.28% | -0.53% | +1.55% |
Financials (USD)
Sales 2024 * | 662M | Sales 2025 * | 923M | Capitalization | 7.68B |
---|---|---|---|---|---|
Net income 2024 * | -59M | Net income 2025 * | 108M | EV / Sales 2024 * | 10.5 x |
Net cash position 2024 * | 755M | Net cash position 2025 * | 839M | EV / Sales 2025 * | 7.41 x |
P/E ratio 2024 * |
-116
x | P/E ratio 2025 * |
64.3
x | Employees | 610 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.33% |
Latest transcript on Intra-Cellular Therapies, Inc.
1 day | +1.28% | ||
1 week | -0.53% | ||
Current month | +1.28% | ||
1 month | +6.53% | ||
3 months | +6.66% | ||
6 months | +42.97% | ||
Current year | +1.55% |
Managers | Title | Age | Since |
---|---|---|---|
Sharon Mates
CEO | Chief Executive Officer | 71 | 13-08-28 |
Director of Finance/CFO | 67 | 13-08-28 | |
Michael Halstead
PSD | President | 51 | 14-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Rory Riggs
BRD | Director/Board Member | 71 | 14-01-07 |
Joel Marcus
BRD | Director/Board Member | 76 | 13-08-28 |
Director/Board Member | 67 | 14-01-07 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.14% | 16 M€ | -5.68% | ||
0.45% | 0 M€ | 0.00% | - | |
0.40% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-01 | 72.73 | +1.28% | 714,823 |
24-04-30 | 71.81 | -0.68% | 840,680 |
24-04-29 | 72.3 | -1.31% | 552,276 |
24-04-26 | 73.26 | +1.57% | 594,803 |
24-04-25 | 72.13 | -1.35% | 658,777 |
Delayed Quote Nasdaq, May 01, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.55% | 7.58B | |
-3.88% | 86.85B | |
+2.76% | 40.16B | |
-16.48% | 31.28B | |
+57.86% | 25.27B | |
-13.58% | 15.33B | |
-9.12% | 11.96B | |
-42.56% | 11.61B | |
+6.89% | 8.83B | |
-7.02% | 7.94B |
- Stock Market
- Equities
- ITCI Stock